

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

LIGAND PHARMACEUTICALS INC  
Form SC 13G  
February 09, 2004

SECURITIES EXCHANGE COMMISSION

Washington, DC 20549

Under the Securities Exchange Act of 1934  
(Amendment No. 2)

LIGAND PHARMACEUTICALS, INC.  
(Name of Issuer)  
Common  
(Title of Class of Securities)

Date of Event Which Requires Filing of this Statement  
December 31, 2003

Check the appropriate box to designate the rule  
pursuant to which this Schedule is filed

Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

53220K207

(CUSIP NUMBER)

1)	Name of Reporting Person	Pioneer Global Asset Management S.p.A.
	IRS Identification No. of Above	13-1961193
2)	Check the Appropriate Box of A Member of Group (See Instructions)	(a) (b) X
3)	SEC Use Only	
4)	Citizenship of Place of	

## Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

	Organization	Italy												
	Number of Shares Beneficially Owned by Each Reporting Person With	<table border="0" style="width: 100%;"> <tr> <td style="width: 10%;">(5) Sole Voting Power</td> <td style="width: 10%;"></td> <td style="width: 80%; text-align: right;">3,928,270</td> </tr> <tr> <td>(6) Shared Voting Power</td> <td></td> <td style="text-align: right;">0</td> </tr> <tr> <td>(7) Sole Dispositive Power</td> <td></td> <td style="text-align: right;">3,928,270</td> </tr> <tr> <td>(8) Shared Dispositive Power</td> <td></td> <td style="text-align: right;">0</td> </tr> </table>	(5) Sole Voting Power		3,928,270	(6) Shared Voting Power		0	(7) Sole Dispositive Power		3,928,270	(8) Shared Dispositive Power		0
(5) Sole Voting Power		3,928,270												
(6) Shared Voting Power		0												
(7) Sole Dispositive Power		3,928,270												
(8) Shared Dispositive Power		0												
9)	Aggregate Amount Beneficially Owned by Each Reporting Person	3,928,270												
10)	Check if the aggregate Amount in Row (9) Exclude Certain Shares (See Instructions)													
11)	Percent of Class Represented By Amount in Row 9.	5.10%												
12)	Type of Reporting Person (See Instructions)	IA												

Item 1(a) Name of Issuer.

LIGAND PHARMACEUTICALS, INC.

Item 1(b) Address of Issuer's Principal Executive Offices:

10275 Science Center Drive  
San Diego, CA 92121

Item 2(a) Name of Person Filing:

Pioneer Global Asset Management S.p.A.

Item 2(b) Address of Principal Business Office:

6 Galleria San Carlo 6  
20122 Milan, Italy

Item 2(c) Citizenship:

Italy

Item 2(d) Title of Class of Securities:

Common Stock

Item 2(e) CUSIP Number:

53220K207

Item 3 The person filing this statement pursuant to Rule 13d-1(b) or 13d-2(b) is:

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

Inapplicable

Item 4. Ownership.

(a) Amount Beneficially Owned: 3,928,270

(b) Percent of Class: 5.10%

(c) Number of shares as to which such person has

(i) sole power to vote or to direct the vote 3,928,270 (ii) shared power to vote or to direct vote 0

(iii) sole power to dispose or to direct disposition of 3,928,270

(iv) shared power to dispose or to direct disposition 0

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date Hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check here:

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Inapplicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported On By the Parent Holding Company.

Inapplicable.

Item 8. Identification and Classification of Members of the Group.

Inapplicable.

Item 9. Notice of Dissolution of the Group.

Inapplicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transactions having such purposes or effect.

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

After reasonable inquiry and to the best of my knowledge and believe, I certify that the information set forth in this statement is true, complete and correct.

February 6, 2004  
Date

/s/Dario Frigerio  
Dario Frigerio  
Chief Executive Officer